Presentation and Status in Health Basket
Presentation | Basket | Yarpa | Pharmasoft |
---|---|---|---|
Tablets 30 X 75 mg (Blister) |
89487 | 3941 | |
Tablets 30 X 75 mg (Bottle) |
80638 | 3961 |
Related information
Dosage
See prescribing information for full details.
Indications
For the prevention of atherothrombotic events as follows: Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease. Patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. For patients with a history of recent MI, recent stroke, or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.For patients with acute coronary syndrome Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) or ST segment elevation acute MI in combination with acetylsalicylic acid (ASA) in medicdbally treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, clopidogrel has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.
Contra-Indications
Hypersensitivity to the active substance or to any of the excipients of the product. Severe liver impairment. Active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Lactation.
Special Precautions
Please contact manufacturer/distributing company for full details.
Side Effects
Please contact manufacturer/distributing company for full details.
Drug interactions
Please contact manufacturer/distributing company for full details.